Eric Stonestreet, of Television’s Hit Comedy, “Modern Family” Joins Forces with Bristol-Myers Squibb to Launch Ready. R...
May 19 2015 - 8:00AM
Business Wire
- Ready. Raise. Rise. encourages
everyone touched by cancer to create a personalized, virtual flag
in honor of a loved one and help raise money for cancer advocacy
organizations
- New survey shows lack of understanding
of Immuno-Oncology and underscores need for greater education on
cancer research
A new survey shows that the overwhelming majority of Americans
(85%) report cancer research is important to them; however, only 15
percent are knowledgeable about Immuno-Oncology – a rapidly
evolving area of research that seeks to harness the body’s own
immune system to help fight cancer.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20150519005620/en/
(Photo: Business Wire)
This press release has an accompanying Smart
Marketing Page providing further details about the organization,
products and services introduced below. You can access the Smart
Marketing Page via the following link:
http://smp.newshq.businesswire.com/pages/eric-stonestreet-televisions-hit-comedy-modern-family-joins-forces-bristol-myers-squibb-laun-0.
To raise awareness of this new area of science, two-time Emmy®
award-winning actor Eric Stonestreet, of television’s hit comedy
“Modern Family,” has teamed up with Bristol-Myers Squibb to launch
Ready. Raise. Rise. – a national campaign that informs
people of the rapidly evolving research and taps into the
collective power of social media platforms to share information
about Immuno-Oncology and raise money to support the cancer
community.
“Like many Americans, my life has been touched by cancer too
many times, and I’ve seen firsthand the devastating impact the
disease has on families and friendships,” said Eric Stonestreet.
“Over the last several decades, we’ve seen great progress and
innovation in cancer research, which is why I’ve joined Ready.
Raise. Rise. This campaign aims to raise awareness of research
like Immuno-Oncology and honors our friends, family members and
loved ones who have fought so bravely against cancer."
As part of the campaign, Stonestreet is asking people to go to
ReadyRaiseRise.com to create a flag in honor of someone who has
been affected by cancer – whether it be themselves or a loved one.
Each person who raises a flag can select a cancer advocacy
organization they wish to support and share their flag on social
media using the hashtag #raiseyourflag. The three advocacy groups
with the most flags raised on their behalf will receive a
charitable donation of $25,000, $50,000 and $75,000 from
Bristol-Myers Squibb.
“Immuno-Oncology research has the potential to change our
approach to fighting cancer today,” said Sanjiv Agarwala, MD, chief
of medical oncology and hematology at St. Luke’s Cancer Center in
Bethlehem, PA, and professor of medicine at Temple University
School of Medicine in Philadelphia, PA. “It is different from other
options – surgery, radiation and chemotherapy – because
Immuno-Oncology aims to work with the body’s own natural defenses
to help fight the disease. It is important that this discussion
continues to gain momentum so that more people learn about this
innovative cancer research and the possibility to provide a longer
life for patients.”
The national survey revealed that while 86 percent of Americans
believe progress is being made in cancer research, nearly all (93%)
believe more information needs to be available about different
types of cancer approaches. Other survey results showed:
- Only 39 percent know that the immune
system can help to fight some cancers
- Yet, one in three Americans (33%) find
the concept of Immuno-Oncology research – harnessing the body’s
immune system to help attack cancer – the most exciting approach to
fighting cancer
- The vast majority of Americans (87%)
want to learn more about this research
“Bristol-Myers Squibb is dedicated to fighting cancer, both
through our robust research and discovery programs in
Immuno-Oncology and also by empowering patients and caregivers with
the knowledge to make the most informed decisions,” said Joseph
Leveque, MD, vice president, Oncology, U.S. Medical, Bristol-Myers
Squibb. “We hope that Ready. Raise. Rise. will help educate
the public about advances in cancer research, recognize patients
and scientists who have contributed to the tremendous developments
in this area, instill hope throughout the cancer community and
inspire continued progress for the future.”
Immuno-Oncology at Bristol-Myers Squibb
While surgery, radiation, and chemotherapy continue to represent
the standard of cancer care, the potential for a longer life has
remained elusive for patients with advanced cancer.
To address this unmet medical need, Bristol-Myers Squibb is
leading research in an innovative field of cancer research known as
Immuno-Oncology, which involves agents whose primary mechanism aims
to work directly with the body’s immune system to help fight
cancer. The company is exploring a variety of compounds and
immunotherapeutic approaches for patients with different types of
cancer, including researching the potential of combining
Immuno-Oncology agents that target different and complementary
pathways in the treatment of cancer.
Bristol-Myers Squibb is committed to advancing the science of
Immuno-Oncology, with the goal of offering the potential for a
longer life and a renewed sense of hope for patients with advanced
cancer.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit www.bms.com, or
follow us on Twitter at http://twitter.com/bmsnews.
About the Survey and TNS
TNS conducted the survey. TNS, the world’s largest custom
research agency, is a well- recognized research group for their
quality and authoritative research.
Participants in the 11-question,
self-administered online omnibus survey were a
nationally-representative sample of 2,500 Americans 18 years of age
and older. The study was conducted from February 12, 2015 –
February 16, 2015 using the field services of TNS. The margin of
sampling error for total Americans at the 95% level of confidence
is ±1.9%. The margin of sampling error for Americans who are cancer
sufferers/survivors at the 95% level of confidence is ±6.7%. Data
are weighted to reflect accurate representation of the
population.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150519005620/en/
Media:Bristol-Myers SquibbLaurel Sacks,
609-897-2944Laurel.sacks@bms.comorOgilvy Public
RelationsKate Fisher, 917-301-8406Kate.fisher@ogilvy.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024